632620-24-7

Basic information

• Product Name: 7-AMINO-1,8-NAPHTHYRIDIN-2(1H)-ONE SULFATE
• Synonyms: 7-AMINO-1,8-NAPHTHYRIDIN-2(1H)-ONE SULFATE
• CAS NO: 632620-24-7
• Molecular Formula: C₈H₇N₃O*H₂O₄S
• Molecular Weight: 0
• Mol File: 632620-24-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 7-AMINO-1,8-NAPHTHYRIDIN-2(1H)-ONE SULFATE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-AMINO-1,8-NAPHTHYRIDIN-2(1H)-ONE SULFATE(632620-24-7)
• EPA Substance Registry System: 7-AMINO-1,8-NAPHTHYRIDIN-2(1H)-ONE SULFATE(632620-24-7)

Safety Data

• Hazardous Substances Data: 632620-24-7(Hazardous Substances Data)

Usage

Description

7-AMINO-1,8-NAPHTHYRIDIN-2(1H)-ONE SULFATE, also known as amonafide sulfate, is a chemical compound that features a naphthyridine ring system with an amino group and a carbonyl group. It is recognized for its antitumor properties and is commonly utilized in the treatment of breast cancer and leukemia.
Used in Pharmaceutical Industry:
7-AMINO-1,8-NAPHTHYRIDIN-2(1H)-ONE SULFATE is used as an antitumor agent for its ability to inhibit topoisomerase II, an enzyme crucial in DNA replication and repair. This inhibition leads to the suppression of tumor growth, making it a valuable component in cancer treatment protocols.
Used in Cancer Treatment:
7-AMINO-1,8-NAPHTHYRIDIN-2(1H)-ONE SULFATE is used as a therapeutic agent for the treatment of breast cancer and leukemia due to its effectiveness in inhibiting the growth of tumor cells by targeting essential DNA processes.
Used in Clinical Research:
7-AMINO-1,8-NAPHTHYRIDIN-2(1H)-ONE SULFATE is used as a subject of clinical trials to further investigate its potential in cancer treatment and to explore any additional therapeutic applications it may have.

Upstream product

• 141-86-6 2.6-diaminopyridine 
• 617-48-1 malic acid 

Downstream Products

• 846031-29-6 C₂₃H₂₉ClN₄O₂ 
• 846031-35-4 C₂₃H₂₆ClF₃N₄O₂ 
• 1309857-71-3 C₂₃H₂₆ClF₃N₄O₂ 
• 846033-37-2 7-Fluoro-1H-[1,8]naphthyridin-2-one 
• 133737-32-3 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone 
• 1931-44-8 2-amino-8H-7-oxo-[1,8]-naphthyridine 
• 55112-41-9 2-hydroxy-7-N-phthalimidyl-1,8-naphthyridine 

Relevant articles and documents

Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder

The synthesis and structure-activity relationship (SAR) of a novel series of aryl piperazine napthyridinone D2 partial agonists is described. Our goal was to optimize the affinities for the D2, 5-HT2A and 5-HT1A receptors, such that the D2/5-HT2A ratio was greater than 5 to ensure maximal occupancy of these receptors when the D2 occupancy reached efficacious levels. This strategy led to identification of PF-00217830 (2) with robust inhibition of sLMA (MED = 0.3 mg/kg) and DOI-induced head twitches in rats (31% and 78% at 0.3 and 1 mg/kg) with no catalepsy observed at the highest dose tested (10 mg/kg).

An Efficient and Cost-Effective Synthesis of Pagoclone

The compound (+)-2-(7-chloro-1,8-naphthyridin-2-yl)-3S-(5-methyl-2- oxohexyl)-l-isoindolinone (pagoclone) shows anxiolytic activity due to partial agonism of the benzodiazepine site of the GABAA receptor. We describe the development of an economical and practical process for a 100+ kg pilot plant production used to supply development needs. For the key reaction, a β-keto phosphonium salt was prepared by selectively reacting a primary α-bromo ketone with triphenylphosphine in the presence of a secondary α-bromo ketone. A novel Wittig reaction with a 1-isoindolinone was used to produce racemic pagoclone. The enantiomerically pure drug substance was prepared by hydrolyzing a γ-lactam and resolving the resulting enantiomeric carboxylic acids with (+)-ephedrine hemihydrate. An alternate resolution, involving chiral multicolumn chromatography (MCC) was also developed. The synthesis was completed by a racemization-free lactam formation to afford pagoclone.